Joachim Böttcher
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Joachim Böttcher has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Alexander Pfeil
Rheumazentrum (G-BA-Regeln) sowie Sektion Rheumatologie und Osteologie, Klinik für Innere Medizin III, Universitätsklinikum Jena, Friedrich-Schiller-Universität Jena, Jena, Deutschland
2 shared publications - Bianca Lassen-Schmidt
Fraunhofer Institute for Digital Medicine MEVIS, Bremen, Germany
2 shared publications - Diane Miriam Renz
Institut für Diagnostische und Interventionelle Radiologie, Arbeitsbereich Kinderradiologie, Medizinische Hochschule Hannover, Hannover, Deutschland
2 shared publications - Felix Güttler
Institute of Diagnostic and Interventional Radiology, Jena University Hospital, Friedrich Schiller University Jena, Jena, GERMANY
2 shared publications - Gunter Wolf
Department of Internal Medicine III, University Hospital Jena, Am Klinikum 1, 07747 Jena, Germany
2 shared publications - Luis Benedict Brüheim
Department of Internal Medicine III, Center of Rheumatology, Jena University Hospital, Friedrich Schiller University Jena, Jena, Germany
2 shared publications
Latest Publications
- Open Access
- 12 August 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (9) , 1-12
The association of symptoms, pulmonary function test and computed tomography in interstitial lung disease at the onset of connective tissue disease: an observational study with artificial intelligence analysis of high-resolution computed tomography
Interstitial lung disease (ILD) is a common and serious organ manifestation in patients with connective tissue disease (CTD), but it is uncertain whether there is a difference in ILD between symptomatic and asymptomatic patients. Therefore, we conducted a study to evaluate differences in the extent of ILD based on radiological findings between symptomatic/asymptomatic patients, using an artificial intelligence (AI)-based quantification of pulmonary high-resolution computed tomography (AIpqHRCT). Within the study, 67 cross-sectional HRCT datasets and clinical data (including pulmonary function test) of consecutively patients (mean age: 57.1 ± 14.7 years, woman n = 45; 67.2%) with both, initial diagnosis of CTD, with systemic sclerosis being the most frequent (n = 21, 31.3%), and ILD (all without immunosuppressive therapy), were analysed using AIqpHRCT. 25.4% (n = 17) of the patients with ILD at initial diagnosis of CTD had no pulmonary symptoms. Regarding the baseline characteristics (age, gender, disease), there were no significant difference between the symptomatic and asymptomatic group. The pulmonary function test (PFT) revealed the following mean values (%predicted) in the symptomatic and asymptomatic group, respectively: Forced vital capacity (FVC) 69.4 ± 17.4% versus 86.1 ± 15.8% (p = 0.001), and diffusing capacity of the lung for carbon monoxide (DLCO) 49.7 ± 17.9% versus 60.0 ± 15.8% (p = 0.043). AIqpHRCT data showed a significant higher amount of high attenuated volume (HAV) (14.8 ± 11.0% versus 8.9 ± 3.9%; p = 0.021) and reticulations (5.4 ± 8.7% versus 1.4 ± 1.5%; p = 0.035) in symptomatic patients. A quarter of patients with ILD at the time of initial CTD diagnosis had no pulmonary symptoms, showing DLCO were reduced in both groups. Also, AIqpHRCT demonstrated clinically relevant ILD in asymptomatic patients. These results underline the importance of an early risk adapted screening for ILD also in asymptomatic CTD patients, as ILD is associated with increased mortality.
- 12 August 2025
- Published by Springer Nature in Rheumatology International
- Vol. 45 (9) , 1-12
Open AccessThe association of symptoms, pulmonary function test and computed tomography in interstitial lung disease at the onset of connective tissue disease: an observational study with artificial intelligence analysis of high-resolution computed tomography
Interstitial lung disease (ILD) is a common and serious organ manifestation in patients with connective tissue disease (CTD), but it is uncertain whether there is a difference in ILD between symptomatic and asymptomatic patients. Therefore, we conducted a study to evaluate differences in the extent of ILD based on radiological findings between symptomatic/asymptomatic patients, using an artificial intelligence (AI)-based quantification of pulmonary high-resolution computed tomography (AIpqHRCT). Within the study, 67 cross-sectional HRCT datasets and clinical data (including pulmonary function test) of consecutively patients (mean age: 57.1 ± 14.7 years, woman n = 45; 67.2%) with both, initial diagnosis of CTD, with systemic sclerosis being the most frequent (n = 21, 31.3%), and ILD (all without immunosuppressive therapy), were analysed using AIqpHRCT. 25.4% (n = 17) of the patients with ILD at initial diagnosis of CTD had no pulmonary symptoms. Regarding the baseline characteristics (age, gender, disease), there were no significant difference between the symptomatic and asymptomatic group. The pulmonary function test (PFT) revealed the following mean values (%predicted) in the symptomatic and asymptomatic group, respectively: Forced vital capacity (FVC) 69.4 ± 17.4% versus 86.1 ± 15.8% (p = 0.001), and diffusing capacity of the lung for carbon monoxide (DLCO) 49.7 ± 17.9% versus 60.0 ± 15.8% (p = 0.043). AIqpHRCT data showed a significant higher amount of high attenuated volume (HAV) (14.8 ± 11.0% versus 8.9 ± 3.9%; p = 0.021) and reticulations (5.4 ± 8.7% versus 1.4 ± 1.5%; p = 0.035) in symptomatic patients. A quarter of patients with ILD at the time of initial CTD diagnosis had no pulmonary symptoms, showing DLCO were reduced in both groups. Also, AIqpHRCT demonstrated clinically relevant ILD in asymptomatic patients. These results underline the importance of an early risk adapted screening for ILD also in asymptomatic CTD patients, as ILD is associated with increased mortality.
- Open Access
- 9 September 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2483-2496
Artificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) for the evaluation of interstitial lung disease in patients with inflammatory rheumatic diseases
High-resolution computed tomography (HRCT) is important for diagnosing interstitial lung disease (ILD) in inflammatory rheumatic disease (IRD) patients. However, visual ILD assessment via HRCT often has high inter-reader variability. Artificial intelligence (AI)-based techniques for quantitative image analysis promise more accurate diagnostic and prognostic information. This study evaluated the reliability of artificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) in IRD-ILD patients and verified IRD-ILD quantification using AIqpHRCT in the clinical setting. Reproducibility of AIqpHRCT was verified for each typical HRCT pattern (ground-glass opacity [GGO], non-specific interstitial pneumonia [NSIP], usual interstitial pneumonia [UIP], granuloma). Additional, 50 HRCT datasets from 50 IRD-ILD patients using AIqpHRCT were analysed and correlated with clinical data and pulmonary lung function parameters. AIqpHRCT presented 100% agreement (coefficient of variation = 0.00%, intraclass correlation coefficient = 1.000) regarding the detection of the different HRCT pattern. Furthermore, AIqpHRCT data showed an increase of ILD from 10.7 ± 28.3% (median = 1.3%) in GGO to 18.9 ± 12.4% (median = 18.0%) in UIP pattern. The extent of fibrosis negatively correlated with FVC (ρ=-0.501), TLC (ρ=-0.622), and DLCO (ρ=-0.693) (p < 0.001). GGO measured by AIqpHRCT also significant negatively correlated with DLCO (ρ=-0.699), TLC (ρ=-0.580) and FVC (ρ=-0.423). For the first time, the study demonstrates that AIpqHRCT provides a highly reliable method for quantifying lung parenchymal changes in HRCT images of IRD-ILD patients. Further, the AIqpHRCT method revealed significant correlations between the extent of ILD and lung function parameters. This highlights the potential of AIpqHRCT in enhancing the accuracy of ILD diagnosis and prognosis in clinical settings, ultimately improving patient management and outcomes.
- 9 September 2024
- Published by Springer Nature in Rheumatology International
- Vol. 44 (11) , 2483-2496
Open AccessArtificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) for the evaluation of interstitial lung disease in patients with inflammatory rheumatic diseases
High-resolution computed tomography (HRCT) is important for diagnosing interstitial lung disease (ILD) in inflammatory rheumatic disease (IRD) patients. However, visual ILD assessment via HRCT often has high inter-reader variability. Artificial intelligence (AI)-based techniques for quantitative image analysis promise more accurate diagnostic and prognostic information. This study evaluated the reliability of artificial intelligence-based quantification of pulmonary HRCT (AIqpHRCT) in IRD-ILD patients and verified IRD-ILD quantification using AIqpHRCT in the clinical setting. Reproducibility of AIqpHRCT was verified for each typical HRCT pattern (ground-glass opacity [GGO], non-specific interstitial pneumonia [NSIP], usual interstitial pneumonia [UIP], granuloma). Additional, 50 HRCT datasets from 50 IRD-ILD patients using AIqpHRCT were analysed and correlated with clinical data and pulmonary lung function parameters. AIqpHRCT presented 100% agreement (coefficient of variation = 0.00%, intraclass correlation coefficient = 1.000) regarding the detection of the different HRCT pattern. Furthermore, AIqpHRCT data showed an increase of ILD from 10.7 ± 28.3% (median = 1.3%) in GGO to 18.9 ± 12.4% (median = 18.0%) in UIP pattern. The extent of fibrosis negatively correlated with FVC (ρ=-0.501), TLC (ρ=-0.622), and DLCO (ρ=-0.693) (p < 0.001). GGO measured by AIqpHRCT also significant negatively correlated with DLCO (ρ=-0.699), TLC (ρ=-0.580) and FVC (ρ=-0.423). For the first time, the study demonstrates that AIpqHRCT provides a highly reliable method for quantifying lung parenchymal changes in HRCT images of IRD-ILD patients. Further, the AIqpHRCT method revealed significant correlations between the extent of ILD and lung function parameters. This highlights the potential of AIpqHRCT in enhancing the accuracy of ILD diagnosis and prognosis in clinical settings, ultimately improving patient management and outcomes.